Holen Sie sich die Stockscreener-App
1.6144
2.52%
0.0244
Schlusskurs vom Vortag:
$1.59
Offen:
$1.58
24-Stunden-Volumen:
6,961
Relative Volume:
0.19
Marktkapitalisierung:
$68.22M
Einnahmen:
$8.98M
Nettoeinkommen (Verlust:
$-48.79M
KGV:
-2.0256
EPS:
-0.797
Netto-Cashflow:
$-36.77M
1W Leistung:
-8.94%
1M Leistung:
-8.43%
6M Leistung:
-32.37%
1J Leistung:
-39.41%
1-Tages-Spanne:
$1.58
$1.615
1-Wochen-Bereich:
$1.58
$1.8199
52-Wochen-Spanne:
$1.51
$2.9319
InspireMD Inc. Stock (NSPR) Company Profile
Firmenname
InspireMD Inc.
Sektor
Branche
Telefon
972 3 6917691
Adresse
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
1.61 | 67.37M | 8.98M | -48.79M | -36.77M | -0.797 |
ABT
Abbott Laboratories
|
102.54 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.84 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.53 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.49 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
79.96 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Eingeleitet | Maxim Group | Buy |
| 2016-01-07 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-03-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2013-11-26 | Eingeleitet | Oppenheimer | Outperform |
InspireMD Inc. Aktie (NSPR) Neueste Nachrichten
InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic - MSN
Published on: 2026-03-28 05:12:59 - baoquankhu1.vn
Market Trends: Will InspireMD Inc stock hit new highs in YEAR2026 Technical Overview & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
CEO Moves: Will InspireMD Inc stock hit new highs in YEAR2026 Sentiment & Proven Capital Preservation Methods - baoquankhu1.vn
InspireMD tops Q4 estimates as revenue jumps, shares rise in premarket trading - MSN
Geopolitics Watch: Can InspireMD Inc keep up with sector leadersMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
InspireMD Q2 2025 Earnings Preview - MSN
InspireMD targets $13M–$15M in 2026 revenue as CGuard Prime gains US traction - MSN
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Johnson & Johnson (JNJ) and InspireMD (NSPR) - The Globe and Mail
InspireMD, Inc. (NSPR) reports Q4 loss, beats revenue estimates - MSN
InspireMD revenue up 62% to USD 3.1M in Q4 2025 - Medical Buyer
Returns Recap: Can InspireMD Inc outperform in the next rallyDay Trade & Safe Entry Trade Reports - baoquankhu1.vn
InspireMD’s Growth Hinges on Real CAS Market Size and Physician Adoption - TipRanks
InspireMD Reports 62% Q4 Revenue Growth and Sets 2026 Outlook for CGuard Prime Carotid Stent System - Minichart
Earnings call transcript: InspireMD Q4 2025: Revenue Surges, EPS Beats By Investing.com - za.investing.com
InspireMD earnings beat by $0.05, revenue topped estimates - Investing.com Canada
InspireMD, Inc. (NSPR) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
InspireMD Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: InspireMD Q4 2025: Revenue Surges, EPS Beats - Investing.com
InspireMD, Inc. Overview: CGuard Carotid Stent Technology, Business Strategy, and Market Leadership in Stroke Prevention 72 - Minichart
InspireMD Reports Strong Q4 2025 Growth and Expansion - TipRanks
FDA PMA and global expansion reshape InspireMD (NSPR) carotid focus - Stock Titan
InspireMD, Inc. (NSPR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
InspireMD, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
InspireMD Q4 net income USD -11.761 million - marketscreener.com
InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
INSPIREMD ($NSPR) Releases Q4 2025 Earnings - Quiver Quantitative
InspireMD (NSPR) revenue climbs 28% in 2025 as net loss widens - Stock Titan
InspireMD Q4 revenue rises 62%, beats estimates - TradingView
NSPR: Q4 2025 revenue surged 62% year-over-year, with 2026 revenue growth projected at up to 65% - TradingView
InspireMD Q4 2025 earnings preview - MSN
InspireMD, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
InspireMD Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
921,587 Shares in InspireMD, Inc. $NSPR Purchased by Ghisallo Capital Management LLC - MarketBeat
Stock Recap: Is InspireMD Inc a momentum stockQuarterly Trade Report & Safe Capital Investment Plans - baoquankhu1.vn
Rosalind Advisors Inc. Purchases 1,616,644 Shares of InspireMD, Inc. $NSPR - MarketBeat
InspireMD (NSPR) price target increased by 25.00% to 5.10 - MSN
Aug Opening: Can InspireMD Inc outperform in the next rally2026 Analyst Calls & Low Drawdown Trading Techniques - baoquankhu1.vn
Aug PreEarnings: Is InspireMD Inc stock risky to hold now2026 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn
InspireMD, Inc. Scheduled to Release Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 - Quiver Quantitative
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Carotid stent developer InspireMD sets March 18 results call - Stock Titan
InspireMD (NSPR) price target decreased by 11.11% to 4.08 - MSN
Is InspireMD Inc. stock dividend yield sustainableWeekly Risk Report & Verified Momentum Watchlists - Naître et grandir
InspireMD announces dismissal of chief operating officer Andrea Tommasoli By Investing.com - Investing.com Australia
InspireMD Announces Planned Departure of Chief Operating Officer - TipRanks
InspireMD announces dismissal of chief operating officer Andrea Tommasoli - Investing.com
Embolic Protection Devices Market to Reach USD 1,161.31 Million by 2032, Growing at a CAGR of 7.58% | DelveInsight - Barchart.com
InspireMD dismisses COO Andrea Tommasoli; last day expected Sept 1, 2026 - TradingView
InspireMD (NSPR) outlines COO dismissal, French-law notice and €61k severance - Stock Titan
InspireMD, Inc. Announces Dismissal of Chief Operating Officer Andrea Tommasoli, Effective April 1, 2026 - marketscreener.com
Finanzdaten der InspireMD Inc.-Aktie (NSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):